List of Excipients in Branded Drug ELETRIPTAN HBR

Generic Drugs Containing ELETRIPTAN HBR

Company	Ingredient	NDC	Excipient
Direct_Rx	eletriptan hbr	72189-439	CELLULOSE, MICROCRYSTALLINE
Direct_Rx	eletriptan hbr	72189-439	CROSCARMELLOSE SODIUM
Direct_Rx	eletriptan hbr	72189-439	FD&C YELLOW NO. 6
Direct_Rx	eletriptan hbr	72189-439	HYPROMELLOSES
Direct_Rx	eletriptan hbr	72189-439	LACTOSE MONOHYDRATE
Direct_Rx	eletriptan hbr	72189-439	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in ELETRIPTAN HBR?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
2	CROSCARMELLOSE SODIUM
2	FD&C YELLOW NO. 6
1	HYPROMELLOSE 2910
1	HYPROMELLOSES
2	LACTOSE MONOHYDRATE

Eletriptan Hydrobromide Excipient Strategy and Commercial Opportunities

Last updated: August 18, 2026

Eletriptan hydrobromide is an immediate-release oral triptan marketed in the United States as Relpax. The commercial opportunity is primarily in generic tablets, orally disintegrating dosage forms, taste-masked products, and differentiated low-cost formulations. The reference product uses a conventional tablet platform with lactose, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, hypromellose, titanium dioxide, triacetin, and yellow ferric oxide.[1]

The most defensible formulation strategy is a bioequivalent immediate-release tablet that preserves rapid disintegration, minimizes excipient-driven dissolution variability, and avoids unnecessary formulation complexity. New dosage forms may require a 505(b)(2) pathway, clinical bridging, or additional comparative studies depending on the claims and formulation changes.

What is eletriptan hydrobromide and how is it formulated?

Eletriptan hydrobromide is the hydrobromide salt of eletriptan, a selective serotonin 5-HT1B/1D receptor agonist indicated for the acute treatment of migraine with or without aura in adults.[1]

Relpax is supplied as film-coated tablets in 20 mg and 40 mg strengths. The label identifies the following inactive ingredients:

Formulation component	Function
Lactose monohydrate	Diluent and tablet mass
Microcrystalline cellulose	Diluent, dry binder, compressibility aid
Croscarmellose sodium	Superdisintegrant
Magnesium stearate	Lubricant
Hypromellose	Film-forming polymer
Titanium dioxide	Opacifier and colorant
Triacetin	Film-coating plasticizer
Yellow ferric oxide	Colorant

The core formulation is compatible with standard direct-compression or dry-granulation manufacturing. The reference excipient system does not indicate a specialized modified-release, lipid-based, or amorphous solid-dispersion platform.

What excipient functions matter most for eletriptan tablets?

Rapid disintegration and reproducible dissolution are the primary formulation targets. Eletriptan products are used for acute migraine treatment, so excessive tablet disintegration time or dissolution variability can reduce the commercial value of a generic product.

Diluent selection

Microcrystalline cellulose is commercially attractive because it supports direct compression and robust tablet hardness at relatively low concentrations. Lactose monohydrate reduces cost and increases tablet mass but introduces potential considerations involving lactose intolerance labeling, moisture behavior, and compatibility with certain manufacturing processes.

Alternative diluents include:

• Mannitol, especially for orally disintegrating tablets
• Dibasic calcium phosphate, where low hygroscopicity is important
• Spray-dried lactose for improved flow and compactability
• Coprocessed excipients combining a filler and binder

A lactose-free generic could provide a minor marketing distinction, but the clinical value is limited because lactose exposure from a small tablet is generally low. The commercial case is stronger in institutional procurement or patient groups with excipient preferences.

Disintegrant selection

Croscarmellose sodium is the reference-product superdisintegrant. Crospovidone and sodium starch glycolate are practical alternatives, but substitution can change:

• Disintegration time
• Dissolution at different pH values
• Tablet friability
• Sensitivity to compression force
• Stability under humidity stress

Crospovidone may support rapid water uptake without the same degree of swelling associated with some other disintegrants. Sodium starch glycolate can provide strong swelling but may be more sensitive to formulation level and processing conditions.

The optimal generic formulation should test disintegrant concentration across the proposed manufacturing design space rather than simply replicate the reference percentage.

Lubrication

Magnesium stearate is widely used, but over-lubrication can reduce tablet wettability and slow dissolution. This is especially relevant when the active ingredient has limited aqueous solubility or when the formulation relies on rapid disintegration to support dissolution.

Potential alternatives include sodium stearyl fumarate and stearic acid. These may improve compatibility with certain processing conditions but require comparative dissolution and stability work. The substitution should be justified by measurable manufacturing or performance benefits.

What formulation patents protect eletriptan products?

The foundational eletriptan composition and use patents were developed before the current generic market. The key historic U.S. patent associated with eletriptan is U.S. Patent No. 5,545,644, assigned to Pfizer, covering eletriptan-related compounds and pharmaceutical compositions.[2]

The patent had a term extending into the mid-2010s, subject to applicable patent-term adjustment, patent-term extension, and pediatric exclusivity. The patent is not a current barrier to ordinary U.S. generic development based solely on its original term.

A formulation developer should distinguish among three categories of intellectual property:

1. Core compound patents. These cover eletriptan or related chemical structures.
2. Method-of-use patents. These may cover treatment of migraine, dosing, or patient populations.
3. Formulation and process patents. These may cover particle size, salt forms, solid-state properties, tablet composition, coating, or manufacturing conditions.

Historic protection for the core compound does not establish that every later formulation patent has expired. A current freedom-to-operate review should examine active U.S., European, Japanese, and other national rights, including continuations, divisionals, and terminal disclaimers.

When did eletriptan lose market exclusivity?

U.S. market exclusivity for Relpax has expired, and generic eletriptan hydrobromide tablets have been approved. The reference product was approved by the FDA in December 2002.[3] The principal compound patent protection extended beyond the initial approval period but did not prevent the subsequent generic market.

The commercial exclusivity timeline is summarized below.

Event	Timing
FDA approval of Relpax	December 2002
Reference strengths	20 mg and 40 mg tablets
Core patent protection	Expired in the mid-2010s, subject to applicable extensions
Generic U.S. approvals	Granted after expiration or resolution of relevant barriers
Current opportunity	Generic tablets and differentiated immediate-release products

Because Orange Book listings and patent statuses can change through corrections, delistings, litigation, or regulatory updates, a launch decision should rely on the current FDA Orange Book and Paragraph IV records rather than historic patent summaries.[4]

What is the Orange Book status of eletriptan hydrobromide?

Eletriptan hydrobromide is an FDA-approved prescription drug with a listed reference product, Relpax. The Orange Book identifies approved products, therapeutic equivalence information, and patent or exclusivity data where applicable.[4]

Generic applicants generally pursue an Abbreviated New Drug Application under section 505(j). A conventional generic tablet must demonstrate pharmaceutical equivalence and bioequivalence to the relevant reference listed drug. The applicant must also address any Orange Book-listed patents through certification.

How do Paragraph IV challenges apply?

A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed product. If an applicant makes a Paragraph IV certification while a relevant listed patent remains in force, the patent holder may initiate litigation within the statutory period, potentially triggering a 30-month stay of approval under the Hatch-Waxman framework.[5]

For eletriptan, the central commercial issue is likely less about the expired core compound patent and more about any later-listed use or formulation rights. A generic developer should assess:

• Current Orange Book patent listings
• Whether the proposed label overlaps a patented use
• Any skinny-label opportunity
• Prior Paragraph IV litigation
• Settlement terms affecting launch timing
• First-filer eligibility and forfeiture risk

What excipient strategy is best for a generic eletriptan tablet?

A low-risk formulation should begin with the reference excipient architecture and optimize only where the change produces a measurable benefit.

Recommended immediate-release platform

Design element	Preferred approach
Dosage form	Film-coated immediate-release tablet
Core process	Direct compression or dry granulation
Diluent	Microcrystalline cellulose with lactose or a lactose-free replacement
Disintegrant	Croscarmellose sodium, crospovidone, or sodium starch glycolate
Lubricant	Magnesium stearate at controlled concentration
Coating	Hypromellose-based film coat
Color	Titanium dioxide and iron oxide, subject to market requirements
Critical performance	Rapid disintegration and discriminatory dissolution

The formulation should control particle-size distribution, blend uniformity, lubricant exposure, compression force, tablet porosity, and coating weight gain. These variables can materially affect dissolution even when the nominal excipient list resembles the reference product.

Excipient compatibility and stability

Potential development risks include:

• Moisture uptake by lactose or hygroscopic excipients
• Lubricant over-coating of drug particles
• Dissolution slowdown after accelerated aging
• Colorant or coating variability
• Tablet capping at high compression speed
• Batch-to-batch changes in active-particle morphology

Stability work should include assay, degradation products, dissolution, water content, hardness, friability, disintegration, and appearance. Packaging should be selected based on measured moisture sensitivity rather than assumed protection requirements.

What commercial opportunities exist beyond generic tablets?

Orally disintegrating tablets

An orally disintegrating eletriptan product could target patients who experience nausea, difficulty swallowing, or limited access to water during a migraine attack. Mannitol, crospovidone, low-substituted hydroxypropyl cellulose, and taste-masking polymers are relevant excipient classes.

The main development barriers are:

• Bitter or persistent drug taste
• Sufficient mechanical strength
• Fast disintegration without excessive friability
• Mouthfeel and residue
• Bioequivalence or bridging requirements
• Packaging protection against moisture

An orally disintegrating tablet would likely require a regulatory strategy beyond a simple conventional ANDA if the dosage form, inactive ingredients, or performance differs materially from the reference product.

Taste-masked granules or sublingual systems

Taste-masked granules could provide a pediatric or dysphagia-oriented opportunity, but eletriptan is indicated for adults. A pediatric product would require an appropriate clinical and regulatory rationale. Sublingual or buccal delivery could produce differentiation, but it would introduce new pharmacokinetic, local-tolerance, and bioequivalence questions.

Fixed-dose migraine products

Combining eletriptan with an analgesic or antiemetic could offer convenience but would face substantial regulatory and commercial barriers. The product would need to establish compatibility, dose justification, interaction management, and benefit over separate administration. A fixed-dose combination is more likely to require a 505(b)(2) application than a straightforward generic pathway.

Patient-friendly excipient positioning

Commercial differentiation may come from:

• Lactose-free formulation
• Reduced-colorant formulation
• Smaller tablet size
• Gluten-free labeling where supportable
• Improved swallowability
• Unit-dose blister packaging
• Low-cost institutional packaging

These attributes are secondary to price, supply reliability, and therapeutic equivalence in a mature generic market.

How does eletriptan compare with competing triptans?

Eletriptan competes with sumatriptan, rizatriptan, zolmitriptan, naratriptan, almotriptan, and newer migraine therapies. Most established triptans are generic, which limits pricing power.

Product	Main commercial form	Generic status	Differentiation opportunity
Eletriptan	Immediate-release tablet	Generic available	ODT, lactose-free, packaging, supply
Sumatriptan	Tablet, nasal, injectable	Generic available	Device and route differentiation
Rizatriptan	Tablet, ODT	Generic available	Rapid-dissolve competition
Zolmitriptan	Tablet, ODT, nasal	Generic available	Nasal and ODT platforms
Naratriptan	Tablet	Generic available	Tolerability and price
Ubrogepant	Tablet	Brand-led	Non-triptan mechanism
Rimegepant	ODT	Brand-led	Orally disintegrating CGRP product

Eletriptan has greater differentiation potential in conventional tablets than in ODT products, where rizatriptan and zolmitriptan already establish strong competitive precedents.

What manufacturing and intellectual-property barriers affect commercialization?

The principal manufacturing barrier is not synthetic complexity alone. Commercial success depends on reproducible particle engineering, blend uniformity, dissolution control, and scalable tablet compression.

Potential IP barriers include:

• Active-particle size or morphology claims
• Salt or polymorph claims
• Solid-state characterization
• Specific dissolution profiles
• Coating or taste-masking systems
• Combination-product claims
• Manufacturing-process claims
• Jurisdiction-specific method-of-use rights

A formulation that uses only conventional excipients may reduce patent exposure but can also make differentiation difficult. A proprietary excipient system can create market positioning but may increase 505(b)(2) risk and litigation exposure.

What revenue exposure and launch scenarios exist?

Relpax revenue is no longer protected by broad branded exclusivity. The market is therefore price-sensitive, with purchasing concentrated among pharmacy benefit managers, wholesalers, retail pharmacies, and government programs.

Three launch scenarios are commercially relevant:

1. Commodity generic tablet. Lowest development risk and fastest regulatory route, but limited margin and high price competition.
2. Differentiated tablet. Moderate formulation and regulatory complexity, with potential value from lactose-free design, smaller size, packaging, or supply reliability.
3. Novel delivery system. Highest development cost and regulatory risk, but greater potential for physician, payer, or patient differentiation.

The strongest near-term opportunity is a reliable, low-cost generic tablet with robust dissolution and supply continuity. The strongest higher-value opportunity is an orally disintegrating or taste-masked product supported by a clear patient-use advantage.

Is biosimilar risk relevant to eletriptan?

No. Eletriptan hydrobromide is a chemically synthesized small-molecule drug, not a biologic. Biosimilar pathways under the Public Health Service Act do not apply. Competitive entry occurs through generic-drug pathways, principally section 505(j), or through a 505(b)(2) application for a materially differentiated formulation or route.[5]

Key Takeaways

• Eletriptan hydrobromide is a mature small-molecule migraine product with generic competition.
• The Relpax reference tablet uses lactose, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and a conventional film coat.
• Rapid disintegration, dissolution consistency, and lubricant control are central formulation priorities.
• Conventional generic tablets offer the lowest regulatory and development risk.
• ODT, taste-masked, lactose-free, and patient-friendly packaging strategies provide the clearest commercial differentiation.
• Biosimilar risk is irrelevant; generic and 505(b)(2) pathways control market entry.
• Current Orange Book listings and national patent records should determine launch timing and Paragraph IV strategy.
• Manufacturing reliability and price competitiveness are likely to matter more than broad formulation patent protection in the mature U.S. market.

FAQs

Can eletriptan hydrobromide be formulated without lactose?

Yes. Mannitol, microcrystalline cellulose, dibasic calcium phosphate, and spray-dried alternatives can replace lactose, subject to compatibility, dissolution, stability, and bioequivalence requirements.

Is an eletriptan orally disintegrating tablet automatically substitutable for Relpax?

No. Substitutability depends on FDA approval, therapeutic-equivalence coding, dosage form, strength, and applicable regulatory requirements.

Does changing magnesium stearate create a new patentable formulation?

Not usually by itself. Patentability would depend on the full formulation, performance characteristics, inventive step, and claim scope.

Can a company launch an eletriptan product with a different film coat?

Yes, if the product satisfies applicable regulatory requirements and does not infringe enforceable formulation, method-of-use, or process patents.

Is eletriptan suitable for a pediatric formulation?

The marketed indication is for adults. A pediatric product would require an appropriate development program, regulatory rationale, and supporting safety and efficacy evidence.

References

1. Pfizer Inc. (2023). Relpax (eletriptan hydrobromide) tablets: U.S. prescribing information. U.S. Food and Drug Administration.

2. U.S. Patent No. 5,545,644. (1996). Pharmaceutical compounds. U.S. Patent and Trademark Office.

3. U.S. Food and Drug Administration. (2002). Relpax approval history and prescribing information. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

5. U.S. Food and Drug Administration. (2017). Approved drug products and patent certifications under the Hatch-Waxman Amendments. FDA.